Hostname: page-component-cd9895bd7-7cvxr Total loading time: 0 Render date: 2024-12-27T06:05:42.971Z Has data issue: false hasContentIssue false
  • English
  • Français

Galantamine in the Treatment of Vascular Dementia

Published online by Cambridge University Press:  10 January 2005

H. Robert Brashear
H. Robert Brashear
Affiliation:
Departments of Neurology and Psychiatric Medicine, University of Virginia Health Services, Charlotte, Virginia, US Johnson and Johnson Pharmaceutical Research and Development, Titusville, New Jersey, US
Get access

Abstract

Vascular dementia (VaD) is a disorder with no cure and limited treatment options. Similarities between VaD and Alzheimer's disease (AD) arise on a number of levels. Both involve progressive decline in cognition, functional ability, and behavior, and there is evidence for a central role of reduced cholinergic neurotransmission in the two illnesses. Treatment strategies in VaD have historically focused on prevention, although evidence of cognitive benefits with preventative treatment is scarce. Acetylcholinesterase inhibitors represent a rational treatment possibility for symptomatic therapy of patients with VaD. A recent large-scale trial of galantamine in patients with VaD or AD with cerebrovascular disease (AD + CVD) represents the first placebo-controlled trial showing clinically relevant benefits in these important patient populations.

Keywords

Cholinesterase inhibitorcerebrovascularcognitive impairmentmulti-infarct
Type
TARGETED THERAPIES
Information
International Psychogeriatrics , Volume 15 , Issue S1 , July 2003 , pp. 187 - 193
Copyright
© 2003 International Psychogeriatric Association

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)